HydroGraph's Graphene to Play Key Role in Lung Cancer Screening
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — HydroGraph Inc. (CSE: HG) (OTCQB: HGRAF), a producer of ultra-pure graphene, today confirmed its material will be a key component in a new lung cancer screening assay developed through a collaboration between Hawkeye Bio (Torrance, California) and Ease Healthcare (Pasadena, California).
Commercialization of the LEAP Test
Under a freshly signed commercialization agreement, Ease Healthcare will bring the LEAP (Lung Enzyme Activity Profile) test to market. The assay incorporates HydroGraph’s patented fractal graphene as part of its biosensor platform.
About the LEAP Diagnostic
LEAP is a blood-based diagnostic designed to detect early-stage lung cancer without radiation exposure. The test is non-invasive and engineered to identify disease signals even in patients who show no symptoms, and it is effective across all lung cancer subtypes.
Targeted Use and Clinical Performance
Initial use will focus on higher-risk groups, including older smokers, veterans, firefighters, and other first responders. Clinical perfor...